Amgen launches 2016 Responsibility Highlights Report14/06/2017
View Full Report
Our mission to serve patients is at the heart of everything we do at Amgen. Our positive contribution to the world also extends beyond making vital medicines. Each year, Amgen dedicates significant resources towards building a better tomorrow.
Amgen’s 2016 Responsibility Highlights Report features selected accomplishments in key areas of Responsibility, including a commitment to patients, support of education and communities, staff safety and wellbeing, and environmental sustainability. The Report also demonstrates Amgen’s unwavering commitment to integrity and compliance in its operations.
Accomplishments highlighted in the report:
- Amgen’s investment of $20 billion in R&D in the last five years
- The Amgen Foundation Matching Gifts Program match of more than $3 million in 2016
- Staff volunteering more than 26,000 hours in 2016
- Amgen’s reduction of carbon emissions by 25 percent and annual water consumption by 27 percent since 2007
- Amgen’s U.S. workforce encompassing a 35 percent minority population in 2016
As evidence of the Company’s broad positive impact, Corporate Responsibility Magazine listed Amgen as one of the 100 Best Corporate Citizens in 2016. In addition, in 2016, Amgen earned placement in the Dow Jones Sustainability World Index for a third year and was named to the North America Index for a fourth year. We were included on the 15th Annual “Top 50 Employers” list in STEM Workforce Diversity Magazine.
The report includes, among other data, environmental sustainability performance data that have been independently verified by Bureau Veritas North America.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Jennifer van der Borgt
+1 (805) 447-5597
View Full Report